This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Momenta Pharmaceuticals' CEO To Present At Morgan Stanley Healthcare Conference (Transcript)

Momenta Pharmaceuticals Inc. (MNTA)

Morgan Stanley Healthcare Conference Call

September 11, 2012, 02:30 pm ET


Craig Wheeler - President and CEO


Dave Friedman - Morgan Stanley



Dave Friedman - Morgan Stanley

Hello, I think we will get started here and thanks everyone for joining us. Dave Friedman, one of the biotech analyst here and in terms of disclosures, you can find personnel and research at Morgan Stanley disclosures on So more exciting things, I've got Craig Wheeler here, CEO and President of Momenta Pharmaceuticals and we're very happy to have you here and the team and maybe if we can start if you can just give, you know, one or two minute overview of the company and you guys have a very unique approach to the drug development world and so maybe a quick intro and then we’ll just jump right in.

Craig Wheeler

Sure. I would be happy to. And for those of you that follow the company long time, you know, it's really a challenge to give a short intro on the complexity of our company in two minutes, but I'll give you just a quick profile of who Momenta is and we're a company that was found and based on really unraveling complexity. I think that’s a simplest way to put it where we look at complex problems like biologics, like heparins and try to understand in much more detail the structure, the manufacturing and the biology of this.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs